UMIN-CTR History

Name：　　UMIN ID：


Unique ID issued by UMIN UMIN000023097
Receipt number R000026621
Scientific Title A phase 2 trial of Gemcitabine+Cisplatin+Bevacizumab regimen for the patients with first recurrence or refractory of ovarian clear cell carcinoma KCOG-G1601
Date of disclosure of the study information 2016/07/11
Last modified on 2022/12/22 13:23:50

No. Disposal Last modified on Item of update
1 Insert 2016/07/10 23:48:03
2 Update 2016/10/27 14:54:33 Narrative objectives1
3 Update 2016/10/27 14:55:59 Email
Email
Email
Email1
4 Update 2018/02/18 09:47:38 Target sample size
5 Update 2019/03/28 14:28:34 Public title
Acronym
Scientific Title
Scientific Title:Acronym
6 Update 2019/03/28 14:29:24 Condition
Narrative objectives1
7 Update 2019/03/28 14:34:13 Interventions/Control_1
Interventions/Control_1
Key inclusion criteria
8 Update 2019/03/28 14:54:43 1st name of lead principal investigator
Last name of lead principal investigator
1st name of lead principal investigator
Last name of lead principal investigator
Zip code
Address
Email

Last name of contact person

Last name of contact person
Zip code
Address
Email
Name of person sending information
Name of person sending information
Address
Email
Email1
Organization
Organization
Address
Address
Tel
Email
9 Update 2019/03/28 14:59:42 UMIN ID1
10 Update 2019/11/28 15:46:49 Recruitment status
Date of IRB
Last follow-up date
11 Update 2020/01/14 08:46:25 Number of participants that the trial has enrolled
12 Update 2021/07/14 13:43:41 Last follow-up date
13 Update 2022/08/04 12:58:46 Other related information
Other related information
14 Update 2022/12/22 13:22:47 Recruitment status
Other related information
Other related information
15 Update 2022/12/22 13:23:50 Publication of results
URL related to results and publications
Date of the first journal publication of results